Article

Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United States

2023-09-08

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Importance</h4> COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. <h4>Objective</h4> To estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children. <h4>Design</h4> A cohort study of children aged 5–17 years vaccinated wi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e3cd3724-4f9c-5806-a2fe-6120a20846ba
DOI: 10.1101/2023.09.06.23294426

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5–17 Years in the United StatesDOI 10.1101/2023.09.06.23294426Read

Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and AdolescentsSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United StatesSemantic proximity Read

Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort StudySemantic proximity Read

Effectiveness of BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-severe diseaseSemantic proximity Read

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 YearsSemantic proximity Read

Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North CarolinaSemantic proximity Read

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United StatesSemantic proximity Read

Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2Semantic proximity Read

BNT162B2 mRNA Covid-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in the Medium - to Long-Term: A Retrospective Cohort StudySemantic proximity Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPPSemantic proximity Read